First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M) Sequist, L. V., Soria, J., Gadgeel, S. M., Wakelee, H. A., Camidge, D., Varga, A., Solomon, B. J., Papadimitrakopoulou, V., Jaw-Tsai, S. S., Caunt, L., Kaur, P., Rolfe, L., Allen, A. R., Goldman, J. AMER SOC CLINICAL ONCOLOGY. 2014

View details for Web of Science ID 000358613204075